Our team supports you in making lasting changes that complement the medications appetite-suppressing effects
Supportive secondary endpoints were not included in the statistical testing hierarchy and were: achievement of weight loss of 20% at week 104
Diabetes 50 , 15621570, doi:10.2337/diabetes.50.7.1562 (2001)
Gault VA, Kerr BD, Harriott P, Flatt PR
#GLP1 #Semaglutide #Tirzepatide #Diabetes #Obesity #Cardiology #Nephrology #MedicalResearch #Endocrinology #HealthcareInnovation #ClinicalTrials To view or add a comment, sign in New Review Highlights Why MASLD/MASH Treatment Is Becoming a Multi-Hormone Strategy A newly published review in Diabetes, Obesity and Metabolism explores how incretin and glucagon signalling pathways are reshaping our understanding of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and its progression to MASH
This makes it all the more critical to consider every potential side effect, not just the typical